Monograph
L01FD01 - Trastuzumab |
Not porphyrinogenic |
NP |
Rationale
No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Trastuzumab is a recombinant DNA-derived humanized anti-HER2 monoclonal antibody.
Therapeutic characteristics
Trastuzumab is an antineoplastic agent used in the treatment of breastcancer. It is administered as an intravenous infusion. Often administered together with paclitaxel, docetaxel or aromatase inhibitor e.g. anastrozol. Common adverse reactions of trastuzumab that can be confused with an acute porphyric attack are vomiting and nausea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
Metabolized as endogenous IgG. Non-CYP metabolism.
Published experience
Used uneventfully for the treatment of breast cancer in AIP woman (Kristiansen, 2006).
IPNet drug reports
No.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Treatment and treatment considerations in a patient with advanced breast cancer and acute intermittent porphyria. Acta Oncol 2006;45(3):337-9.
Kristiansen C, Langkjer ST. |
|
| * | Drug reference publications | |
| 2. | McEvoy GK, editor. Trastuzumab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).
|
|
| 3. | Sweetman SC, editor. Martindale: The complete drug reference. Trasuzumab. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 4. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Herceptin.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac 
Herceptin · Herwenda · Ogivri · Ontruzant · Tuznue · Zercepac 
Herceptin · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Zercepac 
Herceptin · Herzuma · Kanjinti · Ogivri · Trazimera · Zercepac 
Herceptin · Herzuma · Kanjinti · Ontruzant · Trastuzumab · Trastuzumab (Herceptin) 75.6mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Herzuma) 176.4mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Herzuma) 441mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Kanjinti) 105mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Kanjinti) 336mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Kanjinti) 882mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Ontruzant) 378mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Ontruzant) 63mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Trazimera) 147mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Zercepac) 1323mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Zercepac) 54.6mg/250ml in Sodium chloride 0.9% infusion bags · Trastuzumab (Zercepac) 735mg/250ml in Sodium chloride 0.9% infusion bags · Trazimera · Zercepac 
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac 
Herceptin · Ogivri 
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac 
Herceptin · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera 
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac 
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac 
Herceptin · Herwenda · Herzuma · Kanjinti · Ogivri · Ontruzant · Trazimera · Tuznue · Zercepac
© NAPOS 2025